- Home
- Equipment
- switzerland
- pancreas
Show results for
Refine by
Pancreas Equipment Supplied In Switzerland
11 equipment items found
by:Securecell AG based inUrdorf, SWITZERLAND
Our immense knowledge of connecting expansive bioprocessing systems, microfluidics and documenting processes down to the molecular level led us to solutions that could greatly impact the Artificial Pancreas Device System (APDS) market for a significantly underserved diabetes community: unstable type 1 or 2 diabetes patients.1 ...
by:Securecell AG based inUrdorf, SWITZERLAND
Seraccess® innovation begins with an ultra precise / fully automated Glucose ICU monitor and ends with a fully miniaturized / fully mobile artificial pancreas device for personalized life-changing glucose control. ...
Manufactured by:InSphero AG based inSchlieren, SWITZERLAND
3D InSight™ Human Islet Microtissues are a standardized alternative to primary human pancreatic islets for reproducible, reliable, and more efficient research. Expand your GSIS assay window and improve sensitivity to insulin secretagogues with a long-lived, robust model persisting more than 28 days in culture. Eliminate islet pooling and data normalization with islet microtissues ...
by:Debiopharm based inLausanne, SWITZERLAND
Oxaliplatin is a diaminocyclohexane (DACH) platin. It is the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat®, which has dramatically changed the prognosis of colorectal cancer. In 1996, prior to the introduction of oxaliplatin, the standard of care for colorectal cancer was 5-fluorouracil (5-FU). Combination of oxaliplatin with 5-FU and leucovorin (FOLFOX) ...
Manufactured by:BÜHLMANN Laboratories AG based inSchönenbuch, SWITZERLAND
BÜHLMANN fPELA® turbo, the turbidimetric immunoassay, is a flexible solution to be applied on most clinical chemistry analyzers. The technology is a milestone in automation of pancreatic elastase quantification. It allows very rapid and flexible random access use, as well as being the ideal solution for high throughput applications in the routine laboratory. The fPELA turbo assay reduces ...
Manufactured by:InSphero AG based inSchlieren, SWITZERLAND
A standardized in vitro rat islet model for translational diabetes studies and toxicity testing. InSphero 3D InSight™ Rat Islet Microtissues are currently in the final stages of product development and quality control testing. If you are interested in beta testing this product to help us further characterize the model and develop useful ...
Manufactured by:Auris Medical AG based inBasel, SWITZERLAND
The OligoPhore™ / SemaPhore™ technology has been extensively and successfully tested with various siRNA and mRNA sequences in numerous disease models in mice. For the development of our first proprietary drug product, AM-401 (OligoPhore™ siRNA targeting KRAS), we have initiated a program of IND-enabling ...
Manufactured by:Abionic SA based inEpalinges, SWITZERLAND
The IVD CAPSULE PSP is a rapid, single-use in vitro diagnostic test for the determination of Pancreatic Stone Protein (PSP) in blood for the calculation of the cSOFA score at the point of care. The cSOFA score is used to assess the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in ...
Manufactured by:Abionic SA based inEpalinges, SWITZERLAND
The IVD CAPSULE PSP is a rapid, single-use in vitro diagnostic test for the quantitative measurement of pancreatic stone protein (PSP) in blood. The test is intended to be used in conjunction with other clinical assessments and laboratory findings to aid in the early detection of nosocomial sepsis in ...
Manufactured by:Elthera AG based inSchlieren, SWITZERLAND
L1 cell adhesion molecule (L1CAM) is a cell surface protein which is aberrantly expressed in many different tumor types including pancreatic, ovarian, breast, lung, and colorectal cancer. L1CAM expression increases the malignancy of these tumors by promoting cellular proliferation, metastatic spread, tumor angiogenesis, and resistance to chemotherapy. Accordingly, L1CAM-positive tumors ...
Manufactured by:AC BioScience SA based inEpalinges, SWITZERLAND
Our medical objective is to validate and bring to clinical use, a novel approach to improve the treatment of metastatic pancreatic adenocarcinoma using a proangiogenic molecule S1P lyase inhibitor acting as a tumor vascular ...